“GLP-1s are a fertility treatment — they boost your fertility.”
What the evidence shows
In women with obesity- or PCOS-related anovulation (not ovulating), losing weight can rebalance reproductive hormones and restart ovulation — this weight-fertility link is well established in reproductive medicine, and roughly 10% weight loss often improves irregular cycles. GLP-1 drugs drive that weight loss, so fertility can return as a downstream effect. A 2023 meta-analysis of 11 randomized PCOS trials (Zhou et al., 840 women) reported a higher natural pregnancy rate with GLP-1 treatment (relative risk 1.72), and clinicians describe restored ovulation as the main mechanism behind the 'Ozempic babies' phenomenon.
What we still don’t know
Whether GLP-1s do anything for fertility beyond what the weight loss itself does is unproven. The most authoritative 2026 systematic review (Forslund et al., part of the international PCOS guideline evidence base) graded the reproductive benefits as low-certainty and uncertain, built mostly on short trials of older drugs. There is no evidence these drugs help IVF outcomes, and no trial establishes a direct, weight-independent effect on the ovaries.
Why the claim misleads
Calling a GLP-1 a 'fertility treatment' or 'fertility booster' overstates what the data show: the effect is largely weight-mediated, the reproductive evidence is low-certainty, and none of these drugs is FDA-approved for fertility or ovulation induction. It also buries the crucial catch — because they are not recommended in pregnancy and are stopped before conception, they are tools to get healthier before trying, not drugs to take while trying to conceive. Anyone weighing fertility should have that conversation with a clinician, not a marketing page.
Graded by The Peptide Era · evidence, not hype